Constance Ames was named Chief Financial Officer of Tempest Therapeutics, Inc. As of November 6, 2026, Tempest Therapeutics, Inc. has reported 7 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 22, 2026 to October 30, 2026, naming 4 appointments (Form 8-K, September 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Tempest Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-30
- · In / out: In · Person: John Frederick · Role: Director · Effective: 2026-10-13 · 8-K, 2026-10-19
- · In / out: In · Person: Constance Ames · Role: Chief Financial Officer · 8-K, 2026-09-28
- · In / out: In · Person: Nicholas Rossettos · Role: Chief Financial Officer · Effective: 2026-09-01 · 8-K, 2026-08-24
- · In / out: In · Person: Justin Trojanowski · Role: Vice President, Finance · Effective: 2026-06-05 · 8-K, 2026-06-04
Changes7
In (appointed)4
Latest filing2026-10-30
Tempest Therapeutics, Inc. reported changes in 7 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-22 to 2026-10-30. They name 4 people. Every row below is cited to the filing it comes from, and this page adds each new change as Tempest Therapeutics, Inc. files it.
Also on the record for Tempest Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 14, 2026 | Form D, private offering | $7.50M sold | Form D page | Source |
| June 23, 2026 | Form D, private offering | $4.06M sold | Form D page | Source |
| April 3, 2026 | Form D, private offering | $2M sold | Form D page | Source |
| April 2, 2026 | Stake report, Schedule 13D/A, by Versant Venture Capital VI, L.P. | 1.1% of the class | 5%+ stakes | Source |
| March 25, 2026 | Stake report, Schedule 13D/A, by Matthew Angel | 37.4% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13D, by Matthew Angel | 35.9% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13D/A, by Versant Venture Capital VI, L.P. | 3.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tempest Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tempest Therapeutics, Inc. and the records around it.
Tempest Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Form D filing Jun 2026
- 5%+ stake filings Apr 2026
- Who owns it
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Monte Rosa Therapeutics, Inc. (Jan 2026), LENZ Therapeutics, Inc. (Nov 2025), LAVA Therapeutics N.V. (Sep 2025)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Big Tree Cloud Holdings Ltd (Jan 2026)
Watch Tempest Therapeutics, Inc.
Get an email when Tempest Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tempest Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tempest Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-30 | Reported | not named in the filing | 8-K, 2026-10-30 | ||
| 2026-10-19 | In | Director | 2026-10-13 | 8-K, 2026-10-19 | |
| 2026-09-28 | In | Chief Financial Officer | 8-K, 2026-09-28 | ||
| 2026-08-24 | In | Chief Financial Officer | 2026-09-01 | 8-K, 2026-08-24 | |
| 2026-06-04 | In | Vice President, Finance | 2026-06-05 | 8-K, 2026-06-04 | |
| 2026-05-29 | Reported | not named in the filing | 8-K, 2026-05-29 | ||
| 2026-05-22 | Reported | not named in the filing | 8-K, 2026-05-22 |
Who leads Tempest Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John Frederick, appointed, effective 2026-10-13 (filed 2026-10-19).
- Chief Financial Officer: Constance Ames, appointed (filed 2026-09-28).
- Vice President, Finance: Justin Trojanowski, appointed, effective 2026-06-05 (filed 2026-06-04).
Selling to Tempest Therapeutics, Inc.?
New leaders reset buying decisions — get the Full Report on Tempest Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Tempest Therapeutics, Inc. (free up to 3)
Hiring for a seat like this?
Find people with the same kind of experience as the Director at Tempest Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Tempest Therapeutics, Inc.Every change, in the filing's words
Reported
On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. (the "Company") that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal considerations unrelated to the Company, effective immediately.
- Appointment of Chief Financial Officer and Principal Financial and Accounting Officer On October 26, 2026, the Board of Directors of the Company (the "Board") appointed Ms. Stephanie Horn-Warnock as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company, effective immediately.
- Ms. Horn-Warnock, 37, is an experienced financial executive with more than 14 years of experience in accounting, financial reporting, auditing and financial management across the healthcare, pharmaceutical, medical technology, behavioral health and renewable energy industries.
- Since March 2026, she has served in financial leadership and consulting roles through Stout Risius Ross, LLC, including as Controller of Diasome Pharmaceuticals, Inc. and Assistant Controller of Aspargo Labs, Inc., and as an accounting and financial reporting consultant to Lomond Therapeutics Holdings, Inc. From January 2024 to September 2026, Ms. Horn-Warnock was the Vice President of Finance at ROM Technologies Inc., where she led the company's accounting and finance functions, including financial planning and analysis, treasury, financial reporting and regulatory compliance.
- She also oversaw the company's annual audits, internal controls and equity reporting.
- From 2022 to 2024, she served as Senior Manager of Accounting and Assistant Controller at Palmetto Solar, LLC.
Appointed: John Frederick, Director, effective 2026-10-13
Effective October 13, 2026, the Board of Directors (the "Board") of Tempest Therapeutics, Inc. (the "Company") appointed Mr. John Frederick as a Class III director of the Board.
- Mr. Frederick will serve until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- John Frederick, age 62, is a retired senior financial and operating executive with more than three decades of leadership experience across public, private equity-backed and venture-backed companies, principally in technology and technology-enabled businesses.
- From May 2025 to September 2026, he served as Chief Financial Officer of Skillsoft Corp. (NYSE: SKIL) ("Skillsoft") and previously, beginning in August 2024, he served as Skillsoft's Chief Transformation Officer, a position in which he oversaw Skillsoft's business planning.
- From September 2021 to February 2024, prior to his employment at Skillsoft, Mr. Frederick also held strategic leadership positions of increasing responsibility at Indigo Ag, Inc., an agriculture technology company, including Global Head of Carbon Commercial Operations and Chief Financial Officer, where he helped scale the business through a considerable growth phase while reducing core costs and deleveraging the business.
- Mr. Frederick acted as an advisor to Indigo Ag, Inc. from March 2021 through September 2021.
Appointed: Constance Ames, Chief Financial Officer
On September 22, 2026, the Board of Directors of the Company (the "Board") appointed Ms. Constance Ames as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company, effective immediately.
- Appointment of Director and Chair of Audit Committee Effective September 22, 2026, the Board appointed Ms. Nancy Freda-Smith as Class III director to fill a vacancy on the Board.
- Ms. Freda-Smith will serve until the Company's 2027 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
- Ms. Freda-Smith has been appointed to serve as the Chair of the Audit Committee.
- Nancy Freda-Smith, age 54, served as the Chief Audit Executive and Global Head of Asset Protection at Ralph Lauren Corporation, a global leader in the design, marketing, and distribution of premium lifestyle products from 2017 to August 2026.
- At Ralph Lauren, she led various strategic functions, including internal audit, enterprise risk management, and asset protection where her primary responsibility is to identify and assess key business risks relating to cybersecurity, internal controls, and business continuity.
- From 2011 to 2017, Ms. Freda-Smith also served in various vice president positions at Ralph Lauren.
- She has also served as an Independent Director and Audit Committee Member of Chuy's Holdings, providing oversight during its acquisition by Darden Restaurants.
Appointed: Nicholas Rossettos, Chief Financial Officer, effective 2026-09-01
Effective September 1, 2026, the Board of Directors of the Company (the "Board") appointed Mr. Nicholas Rossettos as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company.
- Departure of Principal Financial and Accounting Officer On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the "Company") of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and all other positions he holds with the Company, effective as of September 1, 2026.
- Prior to joining the Company, Mr. Rossettos, 60, served as a financial advisor to TransCode Therapeutics, Inc. (Nasdaq: RNAZ) since April 2025 and as Interim Chief Financial Officer of Sernova Corp. (TSX: SVA), a clinical-stage biotechnology company, from March 2024 to October 2024.
- Since 2012, Mr. Rossettos has provided consulting chief financial officer services to emerging and growth-stage businesses, including as fractional chief financial officer with Charles River CFO.
- Earlier in his career, Mr. Rossettos served as Chief Financial Officer of Egenix, Inc., an early-stage startup focused on cancer therapies, from 2006 to 2012.
- Mr. Rossettos is an experienced chief financial officer and financial executive with more than 30 years of experience supporting private and public companies, with particular expertise in biopharmaceutical and life sciences organizations, corporate finance, capital raising, financial reporting, acquisitions and strategic transactions.
Appointed: Justin Trojanowski, Vice President, Finance, effective 2026-06-05
Effective June 5, 2026, the Board of Directors of the Company (the "Board") appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
- Departure of Chief Financial Officer and Principal Financial Officer On May 29, 2026, Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the "Company") of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.
- Mr. Trojanowski, 37, has served as the Company's Corporate Controller, Treasurer and Principal Accounting Officer since September 2022.
- Previously, Mr. Trojanowski has served as Director, Finance and Assistant Controller from June 2022 through September 2022.
- Prior to joining the Company, Mr. Trojanowski served as Associate Director, Accounting at Nektar Therapeutics, a biopharmaceutical company, from June 2019 to June 2022.
- Prior to Nektar, Mr. Trojanowski served as Senior Manager, Accounting at Immune Design, a late-stage oncology company that was acquired by Merck in 2019, from June 2018 to May 2019.
- Prior to Immune Design, Mr. Trojanowski worked at Ernst & Young, Global Limited, a multinational audit and professional services company, from September 2012 to May 2018, most recently as an Assurance Manager.
- Mr. Trojanowski received his B.S. in Accountancy from Providence College and an M.B.A. in Accountancy from Providence College, and is a Certified Public Accountant.
Reported
On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
- The Separation Agreement provides for the waiver by Ms. Simantov of all accrued and unpaid retainer fees in accordance with the Company's non-employee director compensation program, as described in the Company's Annual Report on Form 10-K/A, filed with the SEC on March 30, 2026.
- The Separation Agreement shall not affect the rights of Ms. Simantov under her outstanding stock option awards or ownership of shares of capital stock of the Company.
- In addition, her indemnification agreement shall remain in full force and effect, with the underlying rights in the Certificate of Incorporation and Bylaws unchanged for six years from separation.
- The foregoing descriptions of the non-employee director compensation program and Separation Agreement do not purport to be complete and are qualified by reference to the full text of each agreement, copies of which will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
Reported
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the "Company") of his or her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
- Each Separation Agreement provides for the waiver by each of the directors of all accrued and unpaid retainer fees in accordance with the Company's non-employee director compensation program, as described in the Company's Annual Report on Form 10-K/A, filed with the SEC on March 30, 2026.
- The Separation Agreements shall not affect the rights of each of these individuals under their outstanding stock option awards or ownership of shares of capital stock of the Company.
- In addition, each of their indemnification agreements shall remain in full force and effect, with the underlying rights in the Certificate of Incorporation and Bylaws unchanged for six years from separation.
- The foregoing description of the non-employee director compensation program and Separation Agreements do not purport to be complete and are qualified by reference to the full text of each agreement, copies of which will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
Tempest Therapeutics, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Tempest Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.